IMV Inc. (IMV)
| Market Cap | 146.93M |
| Revenue (ttm) | 242,742 |
| Net Income (ttm) | -25.93M |
| Shares Out | 82.08M |
| EPS (ttm) | -0.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $1.74 |
| Previous Close | $1.74 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 1.75 |
| Day's Range | 1.70 - 1.80 |
| Day's Volume | 967,948 |
| 52-Week Range | 1.31 - 5.73 |
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Closes Previously Announced Public Offering
IMV Inc (NASDAQ: IMV) has priced its previously-announced underwritten public offering of 14.3 million shares at $1.75 per Unit, for gross proceeds of approximately $25 million. The offer price represe...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Pricing of Public Offering
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, has filed today a preliminary prospectus supplement ...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Announces Annual and Special Meeting of Shareholders Voting Results
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against diffi...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV #Cancer--IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer imm...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to present at two upcoming Investor Conferences
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announce...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV #Cancer--IMV Inc. (the "Company" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapie...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV #BreastCancer--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer i...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV to announce First Quarter 2021 Results and host conference call and Webcast on May 12, 2021
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference
Investors need to pay close attention to IMV stock based on the movements in the options market lately.
Following feedback from the FDA, IMV Inc (NASDAQ: IMV) has inked an agreement with Merck & Co (NYSE: MRK) to initiate a Phase 2B trial evaluating IMV's lead compound, maveropepimut-S (DPX-Survivac), in ...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)-- #DLBCL--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV--IMV Inc. (the "Company" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV--IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today...
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV to Announce Fourth Quarter and Fiscal 2020 Financial and Operational Results
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines agai...
Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - On national TV Sat. Dec 12 & Sun. Dec 13, 2020 - BTV-Business Television spotlights the newest mining, cannabis, tech and pharmaceutic...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq:IMV; TSX:IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccin...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against inf...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...
IMV Inc. (IMV) CEO Frederic Ors on Q3 2020 Results - Earnings Call Transcript
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the Company's T ce...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers
HALIFAX, Nova Scotia--(BUSINESS WIRE)---- $IMV #AntibioticDeveloper--Appili Announces Additional $6.3MM US Funding for its ATI-1701 Biodefense Program, working with Ology Bio on a vaccine candidate agai...
HALIFAX, Nova Scotia--(BUSINESS WIRE)---- $IMV #AntibioticDeveloper--Investigators enrolled and dosed the first cluster of participants in Appili's Phase 2 CONTROL clinical trial evaluating favipiravir ...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Re-establishes At-the-Market Facility
IMV has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...
Canada's IMV is a small but high-profile biotechnology company engaged in the development of a COVID-19 vaccine.
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against infectious di...
IMV Inc. (IMV) CEO Frederic Ors on Q2 2020 Results - Earnings Call Transcript
IMV INC (IMV) delivered earnings and revenue surprises of 25.00% and -42.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Second Quarter 2020 Financial Results
IMV is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
IMV INC (IMV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMV (NASDAQ: IMV) shares are trading higher on Wednesday after the company announced it has received CA$4.75 million ($3.59 million) in funding from the Canadian government agencies for a COVID-19 vacci...
IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020
As of late, it has definitely been a great time to be an investor in IMV Inc. (IMV).
IMV saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
About IMV
IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a ... [Read more...]
| Industry Biotechnology | Founded 2000 |
| Stock Exchange NASDAQ | Ticker Symbol IMV |
Financial Performance
In 2020, IMV Inc.'s revenue was 301,000, a decrease of -47.01% compared to the previous year's 568,000. Losses were -34.86 million, 27.4% more than in 2019.